$396 Million is the total value of Vida Ventures Advisors, LLC's 8 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2021 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Dyne Therapeutics, Inc. | 14 | Q4 2023 | 37.4% |
| Allogene Therapeutics, Inc. | 14 | Q4 2023 | 42.5% |
| Kinnate Biopharma, Inc. | 13 | Q4 2023 | 29.3% |
| Kronos Bio, Inc. | 13 | Q4 2023 | 20.4% |
| Praxis Precision Medicines, Inc. | 12 | Q3 2023 | 33.2% |
| Centessa Pharmaceuticals plc | 11 | Q4 2023 | 39.4% |
| LianBio | 9 | Q4 2023 | 12.1% |
| Homology Medicines, Inc. | 9 | Q3 2022 | 5.2% |
| Oyster Pt Pharma Inc | 5 | Q3 2021 | 10.3% |
| Assembly Biosciences, Inc. | 4 | Q2 2021 | 4.6% |
View Vida Ventures Advisors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-12 |
| 13F-HR | 2024-01-05 |
| 13F-HR | 2023-10-03 |
| 13F-HR | 2023-07-19 |
| 13F-HR | 2023-04-13 |
| 13F-HR | 2023-02-08 |
| 13F-HR | 2022-10-05 |
| 13F-HR | 2022-07-15 |
| 13F-HR | 2022-05-04 |
| 13F-HR | 2022-02-10 |
View Vida Ventures Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.